BRIEF-Praxis Precision Medicines Announces Alignment With FDA

Reuters

Dec 10

BRIEF-<a href="https://laohu8.com/S/PRAX">Praxis Precision Medicines</a> Announces Alignment With FDA

Dec 9 (Reuters) - Praxis Precision Medicines Inc PRAX.O:

PRAXIS PRECISION MEDICINES ANNOUNCES ALIGNMENT WITH FDA ON SIMPLIFIED AND ACCELERATED REGISTRATIONAL PATHWAY FOR ELSUNERSEN IN EARLY ONSET SCN2A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
PRAXIS PRECISION MEDICINES INC: FDA AGREED TO PROPOSED CHANGES TO EMBRAVE3 TRIAL DESIGN TO BE A SINGLE-ARM, BASELINE-CONTROLLED STUDY
PRAXIS PRECISION MEDICINES INC: TOPLINE RESULTS FROM ONGOING EMBRAVE STUDY (PART A, N=9) EXPECTED IN 1H 2026

Source text: ID:nGNXlrcr5

Further company coverage: PRAX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590321401"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590321401\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590321401?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590321401","market":"nz","top_or_hot":-1,"title":"BRIEF-Praxis Precision Medicines Announces Alignment With FDA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> Announces Alignment With FDA </title></head><body><p><span>Dec 9 (Reuters)</span><span> - </span>Praxis Precision Medicines Inc <span>PRAX.O</span>:</p><ul><li><p>PRAXIS PRECISION MEDICINES ANNOUNCES ALIGNMENT WITH FDA ON SIMPLIFIED AND ACCELERATED REGISTRATIONAL PATHWAY FOR ELSUNERSEN IN EARLY ONSET SCN2A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY</p></li><li><p>PRAXIS PRECISION MEDICINES INC:  FDA AGREED TO PROPOSED CHANGES TO EMBRAVE3 TRIAL DESIGN TO BE A SINGLE-ARM, BASELINE-CONTROLLED STUDY</p></li><li><p>PRAXIS PRECISION MEDICINES INC:  TOPLINE RESULTS FROM ONGOING EMBRAVE STUDY (PART A, N=9) EXPECTED IN 1H 2026</p></li></ul><p>Source text: <span>ID:nGNXlrcr5</span></p><p>Further company coverage: <span>PRAX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Praxis Precision Medicines Announces Alignment With FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Praxis Precision Medicines Announces Alignment With FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-10 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> Announces Alignment With FDA </title></head><body><p><span>Dec 9 (Reuters)</span><span> - </span>Praxis Precision Medicines Inc <span>PRAX.O</span>:</p><ul><li><p>PRAXIS PRECISION MEDICINES ANNOUNCES ALIGNMENT WITH FDA ON SIMPLIFIED AND ACCELERATED REGISTRATIONAL PATHWAY FOR ELSUNERSEN IN EARLY ONSET SCN2A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY</p></li><li><p>PRAXIS PRECISION MEDICINES INC:  FDA AGREED TO PROPOSED CHANGES TO EMBRAVE3 TRIAL DESIGN TO BE A SINGLE-ARM, BASELINE-CONTROLLED STUDY</p></li><li><p>PRAXIS PRECISION MEDICINES INC:  TOPLINE RESULTS FROM ONGOING EMBRAVE STUDY (PART A, N=9) EXPECTED IN 1H 2026</p></li></ul><p>Source text: <span>ID:nGNXlrcr5</span></p><p>Further company coverage: <span>PRAX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0QF:1","article_id":"2590321401","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590321401","pubTimestamp":1765314307,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Praxis Precision Medicines Announces Alignment With FDA Dec 9 (Reuters) - Praxis Precision Medicines Inc PRAX.O:PRAXIS PRECISION MEDICINES ANNOUNCES ALIGNMENT WITH FDA ON SIMPLIFIED AND ACCELERA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","PRAX":"Praxis Precision Medicines, Inc."},"translate_title":"简介-Praxis Precision Medicines宣布与FDA达成一致","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":0.9},"content_text":"BRIEF-Praxis Precision Medicines Announces Alignment With FDA Dec 9 (Reuters) - Praxis Precision Medicines Inc PRAX.O:PRAXIS PRECISION MEDICINES ANNOUNCES ALIGNMENT WITH FDA ON SIMPLIFIED AND ACCELERATED REGISTRATIONAL PATHWAY FOR ELSUNERSEN IN EARLY ONSET SCN2A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHYPRAXIS PRECISION MEDICINES INC:  FDA AGREED TO PROPOSED CHANGES TO EMBRAVE3 TRIAL DESIGN TO BE A SINGLE-ARM, BASELINE-CONTROLLED STUDYPRAXIS PRECISION MEDICINES INC:  TOPLINE RESULTS FROM ONGOING EMBRAVE STUDY (PART A, N=9) EXPECTED IN 1H 2026Source text: ID:nGNXlrcr5Further company coverage: PRAX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}